



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/405, 31/35, 31/12</b>		<b>A1</b>	(11) International Publication Number: <b>WO 99/45923</b>
			(43) International Publication Date: 16 September 1999 (16.09.99)
(21) International Application Number: PCT/US99/05061			(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 9 March 1999 (09.03.99)			
(30) Priority Data:			
60/077,913 13 March 1998 (13.03.98) US			
60/078,157 16 March 1998 (16.03.98) US			
9809791.8 7 May 1998 (07.05.98) GB			
9810885.5 20 May 1998 (20.05.98) GB			
60/092,918 15 July 1998 (15.07.98) US			
9822699.6 16 October 1998 (16.10.98) GB			
(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(72) Inventors; and			
(75) Inventors/Applicants (for US only): FISHER, John, E. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). RODAN, Gideon, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
(54) Title: METHODS OF INHIBITING BONE RESORPTION			
(57) Abstract			
The present invention relates to methods of inhibiting bone resorption comprising administering a therapeutically effective amount of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.			
<b>BEST AVAILABLE COPY</b>			
Am4			

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLE OF THE INVENTION  
METHODS OF INHIBITING BONE RESORPTION

BRIEF DESCRIPTION OF THE INVENTION

5           The present invention relates to methods of inhibiting  
abnormal bone resorption comprising administering a therapeutically  
effective amount of a 3-hydroxy-3-methylglutaryl coenzyme A reductase  
inhibitor (hereafter "HMG-CoA reductase inhibitor") to a mammal in  
need thereof. More particularly, the present invention relates to  
10 methods of treating or preventing conditions or disease states involving  
abnormal bone resorption by administering a therapeutically effective  
amount of a HMG-CoA reductase inhibitor.

BACKGROUND OF THE INVENTION

15           A variety of conditions or disease states in humans and  
other mammals involve or are associated with abnormal bone  
resorption. Such disorders include, but are not limited to, osteoporosis,  
Paget's disease, periprosthetic bone loss or osteolysis, hypercalcemia of  
malignancy, osteogenesis imperfecta, osteoarthritis, and alveolar bone  
20 loss associated with periodontal disease. Furthermore, abnormal bone  
resorption is often an undesired side effect associated with  
immunosuppressive therapy and chronic glucocorticoid use. The most  
widespread of the bone resorption disorders is osteoporosis, which in its  
most frequent manifestation occurs in postmenopausal women.  
25 Osteoporosis is a systemic skeletal disease characterized by a low bone  
mass and microarchitectural deterioration of bone tissue, with a  
consequent increase in bone fragility and susceptibility to fracture.  
Because osteoporosis, as well as other disorders associated with  
abnormal bone resorption, are generally chronic conditions, it is believed  
30 that appropriate therapy will generally require chronic treatment.

          Multinucleated cells called osteoclasts are responsible for  
causing bone loss through a process known as bone resorption.  
Osteoclasts are actively motile cells that migrate along the surface of  
bone, and that can bind to bone and secrete acids and proteases causing  
35 a resorption of mineralized bone tissue.

Therapeutic agents that have been used to treat abnormal bone resorption, and osteoporosis in particular, include organic bisphosphonates, estrogens, calcium supplements, the peptide hormone calcitonin, and sodium fluoride. See Riggs et al., *The New England J. of Med.*, Vol. 327, No. 9, pp. 620-627, 1992, which is incorporated by reference herein in its entirety.

It is well known that bisphosphonates are selective inhibitors of osteoclastic bone resorption. The bisphosphonates are important therapeutic agents in the treatment or prevention of a variety of generalized or localized bone disorders caused by or associated with abnormal bone resorption. See H. Fleisch, *Bisphosphonates In Bone Disease, From The Laboratory To The Patient*, 3rd Edition, Parthenon Publishing (1997); U.S. Patent No. 4,621,077, to Rosini et al., issued November 4, 1986; U.S. Patent No. 4,922,007, to Kieczkowski et al., issued May 1, 1990; U.S. Patent No. 5,019, 651, to Kieczkowski et al., issued May 28, 1991; U.S. Patent No. 5,510,517, to Dauer et al., issued April 23, 1996; and U.S. Patent No. 5,648,491, to Dauer et al., issued July 15, 1997; which are all incorporated by reference herein in their entirety.

Despite their therapeutic benefits, bisphosphonates are not well absorbed from the gastrointestinal tract. See B.J. Gertz et al., *Clinical Pharmacology of Alendronate Sodium, Osteoporosis Int.*, Suppl. 3: S13-16 (1993) and B.J. Gertz et al., *Studies of the oral bioavailability of alendronate, Clinical Pharmacology & Therapeutics*, vol. 58, number 3, pp. 288-298 (September 1995), which are both incorporated by reference herein in their entirety. Intravenous administration has been used to overcome this bioavailability problem. However, intravenous administration is costly and inconvenient, especially when the patient must be given an intravenous infusion lasting several hours on repeated occasions.

If oral administration of the bisphosphonate is desired, relatively high doses must be administered to compensate for the low bioavailability from the gastrointestinal tract. To offset the limited bioavailability, it is generally recommended that the patient take the bisphosphonate on an empty stomach and fast for at least 30 minutes after dosing. However, many patients find the need for such fasting on a

daily basis to be inconvenient. Moreover, oral administration has been associated with adverse gastrointestinal effects, especially those relating to the esophagus. See Fleisch, *Id.* These effects appear to be related to the irritant potential of the bisphosphonate in the esophagus, a problem  
5 which is exacerbated by the presence of refluxed gastric acid. For example, the bisphosphonate, pamidronate has been associated with esophageal ulcers. See E.G. Lufkin et al., *Pamidronate: An Unrecognized Problem in Gastrointestinal Tolerability, Osteoporosis International*, 4: 320-322 (1994), which is incorporated by reference  
10 herein in its entirety.

The other above-mentioned anti-bone resorptive therapies also have disadvantages associated with them. Hormone replacement therapy, which involves the administration of estrogen and other compounds having estrogenic activity, is often prescribed for the  
15 treatment of osteoporosis in postmenopausal women. However, such therapy has disadvantages including an increased risk of certain cancers, such as breast cancer, and the development of deep vein thromboses. Also, hormone replacement therapy is contraindicated in premenopausal women and male patients.

20 It has been a long-held belief that the administration of calcium supplements can retard the effects of accelerated bone resorption associated with osteoporosis. However, the benefits, if any, of calcium supplementation alone are relatively small and have yet to be fully demonstrated.

25 The peptide hormone calcitonin is also currently used in the treatment of postmenopausal osteoporosis. However, this hormone has a relatively high molecular weight and has the disadvantage of requiring parenteral or intranasal administration. Also, many patients on calcitonin therapy develop resistance to the material associated with  
30 increased titers of antibodies that neutralize the effectiveness of the therapy.

Although sodium fluoride has been used to stimulate bone formation in osteoporotic women, the resulting bone often has an abnormal fluoride content resulting in structural defects and increased  
35 fragility.

Therefore, even though a number of different agents are known for treating abnormal bone resorption, it is seen that a need clearly exists for finding new therapeutic agents.

It has been reported that perturbation of the cholesterol biosynthetic pathway can have an effect on *in vitro* osteoclast formation, i.e. osteoclastogenesis. See D.E. Hughes et al., Bone, vol. 20, no. 4 (Supp.), April 1997, Abstract No. P362, "Involvement of the Mevalonate Pathway in Osteoclast Apoptosis and the Mechanism of Action of Bisphosphonates"; S.P. Luckman et al., Bone, vol. 20, no. 4 (Supp.), April 1997, Abstract No. P378 "Bisphosphonates and Mevastatin Induce Apoptosis in J774 Macrophages by Inhibition of the Mevalonate Pathway"; and S.P. Luckman et al., Journal of Bone and Mineral Research, vol. 12 (Supp. 1), August 1997, Abstract No. P372 "Bisphosphonates Act By Inhibiting Protein Prenylation"; which are all incorporated by reference herein in their entirety. The HMG-CoA reductase inhibitor, mevastatin, was reported to inhibit *in vitro* osteoclastogenesis formation in bone marrow cultures. It was also reported that this inhibitory effect was partially restored by the addition of mevalonic acid, a metabolite in the cholesterol biosynthetic pathway. However, it has not been demonstrated in any of these references that the administration of a HMG-CoA reductase inhibitor can actually provide a meaningfully significant therapeutic effect in treating bone resorption and the conditions and disease states associated therewith.

The HMG-CoA reductase inhibitors belong to a class of cardiovascular drugs known as anticholesterolemics. Recent studies have unequivocally demonstrated that lovastatin, simvastatin, and pravastatin, which are all members of the HMG-CoA reductase inhibitor class, slow the progression of atherosclerotic lesions in the coronary and carotid arteries. Simvastatin and pravastatin have also been shown to reduce the risk of coronary heart disease events, and in the case of simvastatin, a highly significant reduction in the risk of coronary death and total mortality has been shown by the Scandinavian Simvastatin Survival Study. However, the use of HMG-CoA reductase inhibitors for treating abnormal bone resorption in humans and other mammals is unknown.

Therefore, the present invention provides novel methods of treatment of abnormal bone resorption comprising administering a therapeutically effective amount of an HMG-CoA reductase inhibitor to a mammal in need thereof. The HMG-CoA reductase inhibitors represent  
5 a new class of drugs for treating disorders associated with abnormal bone resorption.

It is therefore an object of the present invention to provide methods for treating abnormal bone resorption and the conditions associated therewith comprising administering a therapeutically  
10 effective amount of a HMG-CoA reductase inhibitor to a mammal in need thereof.

It is another object of the present invention to provide methods for treating or preventing, osteoporosis, Paget's disease, periprosthetic bone loss or osteolysis, hypercalcemia of malignancy,  
15 osteogenesis imperfecta, osteoarthritis, aveolar bone loss associated with periodontal disease, and abnormal bone resorption associated with immunosuppressive therapy or chronic glucocorticoid use, comprising administering a therapeutically effective amount of a HMG-CoA reductase inhibitor to a mammal in need thereof.

It is another object of the present invention to provide pharmaceutical compositions useful for treating abnormal bone resorption comprising a therapeutically effective amount of a HMG-CoA reductase inhibitor.  
20

It is another object of the present invention to provide  
25 methods for treating abnormal bone resorption and the conditions associated therewith by administering a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones,  
30 to a mammal in need thereof.

It is another object of the present invention to provide methods for treating or preventing, osteoporosis, Paget's disease, periprosthetic bone loss or osteolysis, hypercalcemia of malignancy, osteogenesis imperfecta, osteoarthritis, aveolar bone loss associated with  
35 periodontal disease, and abnormal bone resorption associated with

immunosuppressive therapy or chronic glucocorticoid use, comprising administering a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor  
5 modulators, and peptide hormones, to a mammal in need thereof.

It is another object of the present invention to provide pharmaceutical compositions useful for treating abnormal bone resorption comprising a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active  
10 agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones, to a mammal in need thereof.

These and other objects will become readily apparent from the detailed description which follows.

15

## SUMMARY OF THE INVENTION

The present invention relates to a method of inhibiting abnormal bone resorption comprising administering a therapeutically effective amount of a HMG-CoA reductase inhibitor to a mammal in  
20 need thereof.

In further embodiments, the present invention relates to a method of inhibiting abnormal bone resorption comprising administering a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected  
25 from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones, to a mammal in need thereof.

In further embodiments, the present invention relates to a method of treating or preventing a disease state involving abnormal bone resorption.

30

In further embodiments, the present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of the combination of an HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones.



The invention hereof can comprise, consist of, or consist essentially of the essential as well as optional ingredients, components, and methods described herein

## 5 BRIEF DESCRIPTION OF THE FIGURE

Figure 1 shows the inhibition of osteoclastogenesis by lovastatin ("lova", 1 and 10  $\mu$ M) and its reversal by D,L-mevalonic acid lactone ("MVA", 1 mM) as determined using a tartrate resistant acid phosphatase fluorescence assay. Osteoclastogenesis is assessed using a  
10 co-culture of mouse bone marrow cells and MB 1.8 mouse osteoblasts. The lovastatin and D,L-mevalonic acid lactone are added to the co-cultures at days 5 and 6. Tartrate resistant acid phosphatase activity is measured on day 7. Treatments indicated below each bar graph are as follows: A. no treatment, B. 1  $\mu$ M lovastatin, C. 1  $\mu$ M lovastatin and 1  
15 mM D,L-mevalonic acid lactone, D. 10  $\mu$ M lovastatin, and E. 10  $\mu$ M lovastatin and 1 mM D,L-mevalonic acid lactone. Results are reported as percent activity relative to no treatment. The error bars indicate the standard error of the mean. The statistical significance of  $p < 0.001$  for D and E is determined by Fisher PLSD.

20

## DETAILED DESCRIPTION OF THE INVENTION


The present invention relates to methods of inhibiting abnormal bone resorption comprising administering a therapeutically effective amount of a HMG-CoA reductase inhibitor to a mammal in  
25 need thereof. The methods of the present invention are useful for treating or preventing disease states involving abnormal bone resorption. Typically, the therapeutic regimen of the present invention is administered until the desired therapeutic effect is achieved.

The therapeutic agent useful in the present invention is a  
30 compound which inhibits HMG-CoA reductase. Compounds which have inhibitory activity for HMG-CoA reductase can be readily identified by using assays well-known in the art. See U.S. Patent No. 4,231,938, to Monaghan et al., issued November 4, 1980 and U.S. Patent No. 5,354,772, to Kathawal, issued October 11, 1994, both of which are incorporated by  
35 reference herein in their entirety.

Examples of HMG-CoA reductase inhibitors that are useful herein include but are not limited to lovastatin (MEVACOR®; see U.S. Patent No. 4,231,938, already cited above and incorporated by reference herein), simvastatin (ZOCOR®; see U.S. Patent No. 4,444,784, to Hoffman et al., issued April 24, 1984), pravastatin (PRAVACHOL®; see U.S. Patent No. 4,346,227, to Terahara et al., issued August 24, 1982), fluvastatin (LESCOL®; see U.S. Patent No. 5,354,772, already cited above and incorporated by reference herein), atorvastatin (LIPITOR®; see U.S. Patent No. 5,273,995, to Roth, issued December 28, 1993) and cerivastatin (also known as rivastatin; see U.S. Patent No. 5,177,080, to Angerbauer et al., issued January 5, 1993); and mevastatin (compactin, see U.S. Patent No. 3,983,140, to Endo et al, issued September 28, 1976. The patents cited in the previous sentence not already incorporated by reference are also incorporated by reference herein in their entirety.

The structural formulas of these and additional HMG-CoA reductase inhibitors that can be used in the present invention are described at page 87 of M. Yalpani, "Cholesterol Lowering Drugs", Chemistry & Industry, pp. 85-89 (5 February 1996), which is incorporated by reference herein in its entirety. The term HMG-CoA reductase inhibitor is intended to include all pharmaceutically acceptable salts, esters and lactone forms of compounds which have HMG-CoA reductase inhibitory activity, and therefor the use of such salts, esters and lactone forms is included within the scope of this invention. Preferably, the HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, mevastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof. More preferably, the HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof. More preferably, the HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.


Preferred HMG-CoA reductase inhibitors can be represented by the chemical formula



wherein Z is selected from the group consisting of:

5

a)



wherein R<sup>1</sup> is C<sub>1</sub>-C<sub>10</sub> alkyl,


10 R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>3</sub> alkyl, hydroxy, oxo, and C<sub>1</sub>-C<sub>3</sub> hydroxy substituted alkyl,

R<sup>3</sup> is selected from the group consisting of hydrogen, hydroxy, C<sub>1</sub>-C<sub>3</sub> alkyl, and C<sub>1</sub>-C<sub>3</sub> hydroxy substituted alkyl,

a, b, c, and d are all single bonds, or a and c are double bonds, or b and d are double bonds, or one of a, b, c, and d is a double bond, and


15 n is 0, 1, or 2;

b)




wherein X is selected from the group consisting of  $\text{N}[\text{CH}(\text{CH}_3)_2]$  and  $\text{CH}(\text{CH}_2)_3\text{CH}_3$

c)




d)




5

e)



and

f)



wherein R<sup>4</sup> and R<sup>5</sup> are each independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, and trifluoromethyl, and R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, and R<sub>9</sub> are each  
 5 independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, C<sub>1</sub>-C<sub>4</sub> alkyl, and C<sub>1</sub>-C<sub>4</sub> alkoxy. See U.S. Patent No. 5,650,523, to DeCamp et al., issued July 22, 1997, which is incorporated by reference herein in its entirety. The pharmaceutically acceptable salts, esters, and lactone forms of the compounds depicted by  
 10 the preceding chemical formulas are intended to be within the scope of the present invention.

The term "pharmaceutically acceptable salts" as used herein in referring to the HMG-CoA reductase inhibitors shall mean non-toxic salts of the compounds employed in this invention which are  
 15 generally prepared by reacting the free acid with a suitable organic or inorganic base. Examples of salt forms of HMG-CoA reductase inhibitors include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate,  
 20 dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate,  
 25 napsylate, nitrate, oleate, oxalate, pamaote, palmitate, panthothenate, phosphate/diphosphate, polygalacturonate, potassium, salicylate,

sodium, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, valerate, and mixtures thereof.

5 The term "esters" as used herein in referring to the HMG-CoA reductase inhibitors is used in its standard meaning to denote the condensation product of a carboxylic acid and an alcohol. Ester derivatives of the described compounds can function as prodrugs which, when absorbed into the bloodstream of a warm-blooded animal, can cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.

10 The term "lactones" is used herein in referring to the HMG-CoA reductase inhibitors is used in its standard meaning to denote a cyclic condensation product of a carboxylic acid and an alcohol, i.e. a cyclic ester.

15 The term "therapeutically effective amount", as used herein, means that amount of the HMG-CoA reductase inhibitor or that amount of the combination of an HMG-CoA reductase inhibitor and one or more active agents that will elicit the desired biological or medical effect or response sought by a medical doctor, clinician, veterinarian, researcher, or other appropriate professional, when administered in accordance with the desired treatment regimen. A preferred  
20 therapeutically effective amount is a bone resorption inhibiting amount. The term "therapeutically effective amount" is also intended to encompass prophylactically effective amounts, i.e. amounts that are suitable for preventing a disease state or condition, if a prophylactic or  
25 prevention benefit is desired.

The term "abnormal bone resorption", as used herein means a degree of bone resorption that exceeds the degree of bone formation, either locally, or in the skeleton as a whole. Alternatively, "abnormal bone resorption" can be associated with the formation of bone  
30 having an abnormal structure.

The term "bone resorption inhibiting", as used herein, means preventing bone resorption by the direct or indirect alteration of osteoclast formation or activity. Inhibition of bone resorption refers to prevention of bone loss, especially the inhibition of removal of existing

bone either from the mineral phase and/or the organic matrix phase, through direct or indirect alteration of osteoclast formation or activity.

The term "bone resorption inhibiting amount", as used herein, means that amount of the HMG-CoA reductase inhibitor that  
5 will elicit a bone resorption inhibiting effect.

The term "until the desired therapeutic effect is achieved", as used herein, means that the HMG-CoA reductase inhibitor or the combination with another active agent is administered, according to the dosing schedule chosen, up to the time that the clinical or medical effect  
10 sought for the disease or condition being treated or prevented is observed by the clinician or researcher. For the methods of treatment of the present invention, the HMG-CoA reductase inhibitor compound or combination is continuously administered until the desired change in bone mass or structure is observed. In such instances, achieving an  
15 increase in bone mass or a replacement of abnormal bone structure with normal bone structure are the desired objectives. For methods of prevention of the present invention, the HMG-CoA reductase inhibitor compound or combination is continuously administered for as long as necessary to prevent the undesired condition or disease state. In such  
20 instances, maintenance of bone mass density is often the objective. Nonlimiting examples of treatment and prevention administration periods can range from about 2 weeks to the remaining lifespan of the mammal. For humans, administration periods can range from about 2 weeks to the remaining lifespan of the human, preferably from about 2  
25 weeks to about 20 years, more preferably from about 1 month to about 20 years, more preferably from about 6 months to about 10 years, and most preferably from about 1 year to about 10 years.

The dosage regimen utilizing a HMG-CoA reductase inhibitor or the combination with another active agent is selected in  
30 accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt or ester thereof employed. A consideration of these factors is well within the purview of  
35 the ordinarily skilled clinician for the purpose of determining the

therapeutically effective or prophylactically effective dosage amounts needed to prevent, counter, or arrest the progress of the condition. The term "patient" includes mammals, especially humans, who take an HMG-CoA reductase inhibitor or combination for any of the uses  
5 described herein. Administering of the drug or drugs to the patient includes both self-administration and administration to the patient by another person.

The precise dosage of the HMG-CoA reductase inhibitor or the combination with another active agent will vary with the dosing  
10 schedule, the particular compound chosen, the age, size, sex and condition of the mammal or human, the nature and severity of the disorder to be treated, and other relevant medical and physical factors. Thus, a precise pharmaceutically effective amount cannot be specified in advance and can be readily determined by the caregiver or clinician.  
15 Appropriate amounts can be determined by routine experimentation from animal models and human clinical studies.

In particular, for daily dosing, the amounts of the HMG-CoA reductase inhibitor can be the same or similar to those amounts which are employed for anti-hypercholesterolemic treatment and which  
20 are described in the Physicians' Desk Reference (PDR), 52<sup>nd</sup> Ed. of the PDR, 1998 (Medical Economics Co), which is incorporated by reference herein in its entirety. For the additional active agents, the doses can be the same or similar to those amounts which are known in the art.

The HMG-CoA reductase inhibitors and the combination  
25 with other active agents can be administered via a wide variety of routes including oral administration, intravenous administration, intranasal administration, injections, ocular administration, and the like.

A preferred route of delivery is oral administration.

Oral dosage amounts of the HMG-CoA reductase inhibitor  
30 are from about 1 to 200 mg/day, and more preferably from about 5 to 160 mg/day. However, dosage amounts will vary depending on the potency of the specific HMG-CoA reductase inhibitor used as well as other factors as noted above. An HMG-CoA reductase inhibitor which has sufficiently greater potency may be given in sub-milligram daily



dosages. The HMG-CoA reductase inhibitor may be administered from 1 to 4 times per day, and preferably once per day.

- For example, the daily dosage amount for simvastatin can be selected from 5 mg, 10 mg, 20 mg, 40 mg, 80 mg and 160 mg; for
- 5 lovastatin, 10 mg, 20 mg, 40 mg and 80 mg; for fluvastatin sodium, 20 mg, 40 mg and 80 mg; for pravastatin sodium, 10 mg, 20 mg, and 40 mg; and for atorvastatin calcium, 10 mg, 20 mg, and 40 mg.


#### Additional Active Agents For Inhibiting Abnormal Bone Resorption

- 10 Further exemplifying the invention are methods of treatment comprising administering a HMG-CoA reductase inhibitor in combination with one or more active agents for inhibiting bone abnormal resorption selected from the group consisting of organic
- bisphosphonates, estrogen receptor modulators, and peptide hormones.

- 15 These additional active agents for inhibiting bone resorption can be used in combination with the HMG-CoA reductase inhibitor in a single dosage formulation, or may be administered to the patient in a separate dosage formulation, which allows for concurrent or sequential administration.

#### 20 Organic Bisphosphonates

The bisphosphonates useful herein correspond to the chemical formula



25

wherein

A and X are independently selected from the group consisting of H, OH, halogen, NH<sub>2</sub>, SH, phenyl, C1-C30 alkyl, C1-C30 substituted alkyl, C1-C10 alkyl or dialkyl substituted NH<sub>2</sub>, C1-C10 alkoxy,

C1-C10 alkyl or phenyl substituted thio, C1-C10 alkyl substituted phenyl, pyridyl, furanyl, pyrrolidinyl, imidazonyl, and benzyl.

5 In the foregoing chemical formula, the alkyl groups can be straight, branched, or cyclic, provided sufficient atoms are selected for the chemical formula. The C1-C30 substituted alkyl can include a wide variety of substituents, nonlimiting examples which include those selected from the group consisting of phenyl, pyridyl, furanyl, pyrrolidinyl, imidazonyl, NH<sub>2</sub>, C1-C10 alkyl or dialkyl substituted NH<sub>2</sub>, OH, SH, and C1-C10 alkoxy.

10 In the foregoing chemical formula, A can include X and X can include A such that the two moieties can form part of the same cyclic structure.

The foregoing chemical formula is also intended to encompass complex carbocyclic, aromatic and hetero atom structures for the A and/or X substituents, nonlimiting examples of which include naphthyl, quinolyl, isoquinolyl, adamantyl, and chlorophenylthio.

15 Preferred structures are those in which A is selected from the group consisting of H, OH, and halogen, and X is selected from the group consisting of C1-C30 alkyl, C1-C30 substituted alkyl, halogen, and C1-C10 alkyl or phenyl substituted thio.

20 More preferred structures are those in which A is selected from the group consisting of H, OH, and Cl, and X is selected from the group consisting of C1-C30 alkyl, C1-C30 substituted alkyl, Cl, and chlorophenylthio.

25 Most preferred is when A is OH and X is a 3-aminopropyl moiety, so that the resulting compound is a 4-amino-1-hydroxybutylidene-1,1-bisphosphonate, i.e. alendronate.

Pharmaceutically acceptable salts and derivatives of the bisphosphonates are also useful herein. Nonlimiting examples of salts include those selected from the group consisting of alkali metal, alkaline metal, ammonium, and mono-, di, tri-, or tetra-C1-C30-alkyl-substituted ammonium. Preferred salts are those selected from the group consisting of sodium, potassium, calcium, magnesium, and ammonium salts. Nonlimiting examples of derivatives include those selected from the group consisting of esters, hydrates, and amides.

30  
35

"Pharmaceutically acceptable" as used herein means that the salts and derivatives of the bisphosphonates have the same general pharmacological properties as the free acid form from which they are derived and are acceptable from a toxicity viewpoint.

5 It should be noted that the terms "bisphosphonate" and "bisphosphonates", as used herein in referring to the therapeutic agents of the present invention are meant to also encompass diphosphonates, biphosphonic acids, and diphosphonic acids, as well as salts and derivatives of these materials. The use of a specific nomenclature in  
10 referring to the bisphosphonate or bisphosphonates is not meant to limit the scope of the present invention, unless specifically indicated. Because of the mixed nomenclature currently in use by those of ordinary skill in the art, reference to a specific weight or percentage of a bisphosphonate compound in the present invention is on an acid active weight basis,  
15 unless indicated otherwise herein. For example, the phrase "about 70 mg of a bone resorption inhibiting bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof, on an alendronic acid active weight basis" means that the amount of the bisphosphonate compound selected is  
20 calculated based on 70 mg of alendronic acid.

Nonlimiting examples of bisphosphonates useful herein include the following :

Alendronic acid, 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid.

25 Alendronate (also known as alendronate sodium or monosodium trihydrate), 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium trihydrate.

Alendronic acid and alendronate are described in U.S. Patents 4,922,007, to Kieczkowski et al., issued May 1, 1990, and  
30 5,019,651, to Kieczkowski, issued May 28, 1991, both of which are incorporated by reference herein in their entirety.

Cycloheptylaminomethylene-1,1-bisphosphonic acid, YM 175, Yamanouchi (cimadronate), as described in U.S. Patent 4,970,335, to Isomura et al., issued November 13, 1990, which is  
35 incorporated by reference herein in its entirety.

1,1-dichloromethylene-1,1-diphosphonic acid (clodronic acid), and the disodium salt (clodronate, Procter and Gamble), are described in Belgium Patent 672,205 (1966) and *J. Org. Chem* 32, 4111 (1967), both of which are incorporated by reference herein in their  
5 entirety.

1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonic acid (EB-1053).

1-hydroxyethane-1,1-diphosphonic acid (etidronic acid).

1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-  
10 bisphosphonic acid, also known as BM-210955, Boehringer-Mannheim (ibandronate), is described in U.S. Patent No. 4,927,814, issued May 22, 1990, which is incorporated by reference herein in its entirety.

6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid  
15 (neridronate).

3-(dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid (olpadronate).

3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid (pamidronate).

20 [2-(2-pyridinyl)ethylidene]-1,1-bisphosphonic acid (piridronate) is described in U.S. Patent No. 4,761,406, which is incorporated by reference in its entirety.

1-hydroxy-2-(3-pyridinyl)-ethylidene-1,1-bisphosphonic acid (risedronate).

25 (4-chlorophenyl)thiomethane-1,1-disphosphonic acid (tiludronate) as described in U.S. Patent 4,876,248, to Breliere et al., October 24, 1989, which is incorporated by reference herein in its entirety.

1-hydroxy-2-(1H-imidazol-1-yl)ethylidene-1,1-  
30 bisphosphonic acid (zolendronate).

Preferred are bisphosphonates selected from the group consisting of alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zolendronate, pharmaceutically acceptable salts thereof, and mixtures  
35 thereof.

More preferred is alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.

Most preferred is alendronate monosodium trihydrate.

#### Estrogen Receptor Modulators

5 Estrogen receptor modulators are known for use in hormone replacement therapy and for their anti-bone resorption benefits.

Nonlimiting examples of estrogen receptor modulators useful herein include estrogen, progestins, estradiol, raloxifene, and  
10 tamoxifene, and their pharmaceutically acceptable salts, and mixtures thereof.

#### Peptide Hormones

A peptide hormone useful herein is calcitonin, which is approved for use for treating osteoporosis. Both human and salmon  
15 calcitonin are useful herein.

#### Pharmaceutical Compositions

Compositions useful in the present invention comprise a therapeutically effective amount of a HMG-CoA reductase inhibitor. In further embodiments, these compositions also comprise one or more  
20 active agents. The HMG-CoA reductase inhibitor and any other active agents is typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers, collectively referred to herein as "carrier materials", selected with respect to the route of administration, i.e. for example oral administration, intravenous  
25 administration, intranasal administration, injection, or ocular administration.

For oral administration, the composition can be administered in the form of tablets, capsules, elixirs, syrups, powders, and the like, and consistent with conventional pharmaceutical  
30 practices. For solid oral forms, e.g. tablets, capsules, or powders, the HMG-CoA reductase inhibitor and any other active agents can be combined with an oral, non-toxic, pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, croscarmellose sodium and the  
35 like. For liquid oral forms, e.g., elixirs and syrups, the drug component

or components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated. Suitable binders can include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, and corn sweeteners, natural and synthetic gums, such as acacia, guar, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.

The drug or drugs can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

The drug or drugs can also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. Active drug or drugs can also be coupled with soluble polymers as targetable carriers. Such polymers can include polyvinyl-pyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxy-ethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, active drug may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.

The instant invention includes the use of both rapid-release and time-controlled release pharmaceutical formulations.

#### Process for Preparing Pharmaceutical Compositions

The instant invention also encompasses a process for preparing a pharmaceutical composition comprising combining the

HMG-CoA reductase inhibitor and any other active agents with a pharmaceutically acceptable carrier. The instant invention also encompasses the use of an HMG-CoA reductase inhibitor and any other active agents for the preparation of a medicament for inhibiting  
5 abnormal bone resorption.

The following Examples are presented to better illustrate the invention.

10

### EXAMPLE 1

#### Method for Evaluating the Effect of HMG-CoA Reductase Inhibitors on Osteoclastogenesis in Murine Co-Cultures

Murine co-cultures of osteoblasts and marrow cells are  
15 prepared using the methods of Wesolowski, et al., *Exp Cell Res*, (1995), 219, pp. 679-686, which is incorporated by reference herein in its entirety. Bone marrow cells are harvested from 6-week-old male Balb/C mice by flushing marrow spaces of freshly isolated long bones (tibiae and femora) with  $\alpha$ -MEM (minimal essential media) containing  
20 penicillin/streptomycin (100 I.U./ml of each and 20 mM Hepes buffer). The bone marrow cells are suspended in  $\alpha$ -MEM and the cells are filtered through an approximately 70  $\mu$ m cell strainer. The filtrate is centrifuged at about 300 x g for about 7 minutes. The resulting pellet is resuspended in  $\alpha$ -MEM supplemented with fetal calf serum (10 % v/v)  
25 and 10 nM 1, 25-(OH)<sub>2</sub> vitamin D<sub>3</sub>. These bone marrow isolates are added to sub-confluent monolayers of osteoblastic MB 1.8 cells in 24 well cell culture plates and cultured for 5 days at 37°C in the presence of 5% CO<sub>2</sub>. Culture media is replenished daily. Fusion of the osteoclast precursor cells from bone marrow (with each other) to form multinucleated  
30 osteoclast-like cells typically occurs after about 5 days.

The compounds to be evaluated are prepared as a solution of the desired concentration in  $\alpha$ -MEM. Examples of compounds

evaluated include the HMG-CoA reductase inhibitors, lovastatin and simvastatin, as well as compounds that block the effects of these inhibitors, such as D,L-mevalonic acid lactone. Combinations of compounds can also be evaluated. The solutions of the compounds to be evaluated are added to the cultures, typically about 0.5 mL/well, on days 5 and 6. No treatment controls (controls not treated with compounds) are prepared by adding equivalent volumes of  $\alpha$ -MEM to the control wells. On day 7, the cultures are evaluated by counting the number of osteoclast-like cells (stained multinucleated cells) or by measuring the tartrate-resistant acid phosphatase (TRAP) activity of the sample via standard fluorescence techniques using a naphthol-based substrate.

#### Staining and counting of osteoclast like cells

The following solutions are prepared for staining the cultures:

3.7% formalin: 1:10 dilution of 37% formaldehyde in phosphate-buffered 0.9 % NaCl,

HBS: 0.9% NaCl, 10 mM HEPES, pH 7.1,

Acetate/Tartrate buffer: 50 mM sodium acetate, 30 mM sodium tartrate, 0.1% Triton X-100, pH 5.0,

Staining Solution: dissolve Fast Red Violet LB (Sigma # F1625) in acetate/tartrate buffer at 0.3 mg/ml and add 5  $\mu$ l/ml of 20 mg/ml solution of Naphthol AS-MX phosphate in acetate/tartrate buffer (this solution is made fresh just prior to staining).

The cell cultures are fixed for 10 minutes with approximately 0.5 mL of 3.7% formalin at room temperature and then washed once with about 1 mL of the HBS. The staining solution (about 0.5 mL) is added to each well and the plates are then incubated for about 10-20 minutes at about 37°C. Following staining, each plate is washed 3



times with de-ionized water, blotted on paper towels and then allowed to air dry. Multi-nucleated stained cells are counted using an inverted-phase microscope at about 30x magnification.

5 Fluorescence measurements

The following substrate solution is prepared for measuring TRAP activity via fluorescence:

10 Substrate solution: A compound having a naphthol functional group is dissolved at a concentration of 2.5 mg/ml in HBS buffer.

15 The cell cultures are washed with HBS (about 0.5 ml) and then treated with commercially-available trypsin/EDTA (Gibco BRL, Grand Island, NY, 0.25 ml/well) for 10 minutes at 37°C to selectively release the mononuclear multinuclear cells. Following trypsinization the plates are washed 3 times with Hepes and then blotted on paper towels. Next, about 0.5 mL of the naphthol substrate solution is added to each well and the plates are then incubated at 37°C. Reactions are  
20 stopped 1 hour after incubation by addition of 1M NaOH (about 0.05 ml/well). The contents of the wells are swirled by placing the plates on an orbital shaker for about 10 minutes to dissolve any precipitates. Fluorescence is determined using a fluorescence plate reader with the excitation wavelength set at 360 nm and the emission wavelength set at  
25 530 nm.

Using either the visual counting or fluorescence techniques it is demonstrated that HMG-CoA reductase inhibitors inhibit osteoclastogenesis.

## EXAMPLE 2

Tablet composition

<u>Ingredient</u>	<u>Amount per tablet</u>
Simvastatin	5.0 mg
BHA	0.02mg
Ascorbic acid	2.50 mg
Citric acid	1.25 mg
Microcrystalline cellulose	5.0 mg
Pregel starch	10.0 mg
Magnesium stearate	0.5 mg
Lactose	74.73 mg

5 All the ingredients except magnesium stearate are blended  
together in a suitable mixer. The powder mixture is then granulated  
with adequate quantities of granulating solvent(s), e.g. water. The wet  
granulated mass is dried in a suitable dryer. The dried granulation is  
sized through a suitable screen. The sized granulation is mixed with  
magnesium stearate before tableting. The tablets may be coated if  
10 deemed necessary. Additional ingredients that may be added to the  
above include suitable color and mixtures of colors.

The composition is useful for inhibiting abnormal bone  
resorption.

15 In alternative formulations, the simvastatin is replaced by  
an HMG-CoA reductase inhibitor selected from lovastatin, pravastatin,  
fluvastatin, atorvastatin, cerivastatin, and mevastatin.

## EXAMPLE 3

Directly compressed tablet composition

<u>Amount per tablet</u>	<u>Ingredient</u>
5 mg	Lovastatin
116.9 mg	Microcrystalline cellulose
116.9 mg	Lactose anhydrate
7.5 mg	Crosmellose sodium
3.7 mg	Magnesium stearate

5                   The ingredients are combined and blended together and are compressed using conventional tableting techniques.

                  The composition is useful for inhibiting abnormal bone resorption.

10                  In alternative formulations, the lovastatin is replaced by an HMG-CoA reductase inhibitor selected from lovastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, and mevastatin.

## EXAMPLE 4

Hard gelatin capsule composition

15

<u>Amount per capsule</u>	<u>Ingredient</u>
5 mg	Simvastatin
47 mg	Microcrystalline cellulose
47 mg	Lactose anhydrate
1 mg	Magnesium stearate
1 capsule	Hard gelatin capsule

                  The dry ingredients are combined and blended together and encapsulated in a gelatin coating using standard manufacturing techniques.

20                  The composition is useful for inhibiting abnormal bone resorption.

In alternative formulations, the simvastatin is replaced by an HMG-CoA reductase inhibitor selected from lovastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, and mevastatin.

5

## EXAMPLE 5

Oral suspension composition

<u>Amount per 5 mL dose</u>	<u>Ingredient</u>
5 mg	Lovastatin
150 mg	Polyvinylpyrrolidone
2.5 mg	Poly oxyethylene sorbitan monolaurate
10 mg	Benzoic acid
to 5 mL with aqueous sorbitol solution (70%)	

10 An oral suspension is prepared by combining the ingredients using standard formulation techniques.

The composition is useful for inhibiting abnormal bone resorption.

15 In alternative formulations, the lovastatin is replaced by an HMG-CoA reductase inhibitor selected from simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, and mevastatin.

## EXAMPLE 6

Intravenous infusion composition

<u>Amount per 200mL dose</u>	<u>Ingredient</u>
5 mg	Simvastatin
0.2 mg	Polyethylene oxide 400
1.8 mg	Sodium chloride
to 200mL	Purified water

20

The ingredients are combined using standard formulation techniques.

In alternative formulations, the simvastatin is replaced by an HMG-CoA reductase inhibitor selected from lovastatin, pravastatin,  
5 fluvastatin, atorvastatin, cerivastatin, and mevastatin.

## WHAT IS CLAIMED IS:

1. A method of inhibiting abnormal bone resorption comprising administering a therapeutically effective amount of a HMG-CoA reductase inhibitor to a mammal in need thereof.

2. A method according to claim 1 wherein said mammal is a human.

3. A method according to claim 2 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, mevastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.

4. A method according to claim 3 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.

5. A method according to claim 4 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.

6. A method of inhibiting abnormal bone resorption comprising administering a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones to a mammal in need thereof.

7. A method according to claim 6 wherein said mammal is a human.

8. A method according to claim 7 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin,  
5 cerivastatin, mevastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.

9. A method according to claim 8 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of  
10 lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.

10. A method according to claim 9 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of  
15 lovastatin, simvastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.

11. A method according to claim 7 wherein said organic  
20 bisphosphonate is selected from the group consisting of alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zolendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.

25 12. A method according to claim 11 wherein said organic bisphosphonate is alendronate and the pharmaceutically acceptable salts thereof.

13. A method according to claim 12 wherein said organic  
30 bisphosphonate is alendronate monosodium trihydrate.

14. A method according to claim 7 wherein said estrogen  
receptor modulator is selected from the group consisting of estrogen,  
progestins, estradiol, raloxifene, and tamoxifene, and their  
35 pharmaceutically acceptable salts, and mixtures thereof.

15. A method according to claim 7 wherein said peptide hormone is selected from the group consisting of human calcitonin, salmon calcitonin, and mixtures thereof.

5

16. A pharmaceutical composition comprising a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormone.

10

17. A composition according to claim 16 which further comprises a pharmaceutically acceptable carrier.

15

18. A composition according to claim 17 wherein said HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, mevastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.

20

19. A composition according to claim 17 wherein said organic bisphosphonate is selected from the group consisting of alendronate, cimidronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zolendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.

25

20. A composition according to claim 17 wherein said estrogen receptor modulator is selected from the group consisting of estrogen, progestins, estradiol, raloxifene, and tamoxifene, and their pharmaceutically acceptable salts, and mixtures thereof.

30

21. A composition according to claim 17 wherein said peptide hormone is selected from the group consisting of human calcitonin, salmon calcitonin, and mixtures thereof.

35



22. A method of treating or preventing a disease state involving abnormal bone resorption comprising administering a therapeutically effective amount of a HMG-CoA reductase inhibitor to a mammal in need thereof.

5

23. A method according to claim 22 wherein said disease state is osteoporosis.

24. A method of treating or preventing a disease state involving abnormal bone resorption comprising administering a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones to a mammal in need thereof.

10  
15

25. A method according to claim 24 wherein said disease state is osteoporosis.

1/1




FIG.1

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/05061

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/415, 460, 690, 922

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN on line

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Tae Woo J.T. HMG CoA reductase inhibitors reversibly inhibit fusion of mononucleated preosteoclasts and bone resorption by disrupting actin ring formation. Bone, 01 January 1998, Vol. 23 (Suppl.), No. 5, p. 549	NONE1-25



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*a* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

04 JUNE 1999

Date of mailing of the international search report

07 JUL 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MICHAEL BORIN

Telephone No. (703) 308-0956

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/05061

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/05061

A. CLASSIFICATION OF SUBJECT MATTER:  
IPC (6):

A61K 31/405, 31/35, 31/12

A. CLASSIFICATION OF SUBJECT MATTER:  
US CL :

514/415, 460, 690, 922

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**